az10419369
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01085123)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 5-hydroxytryptamine receptor 1BBINDING AGENT
HTR1B binding agent
Chemistry & pharmacology
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Also known as
- az10419369
- az10419369
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01085123 | Phase 1 | May 1, 2010 | AstraZeneca, IQVIA |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2010 |
| IQVIA | For profit | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1